K(Ca)3.1 channel-blockade attenuates airway pathophysiology in a sheep model of chronic asthma. by Van Der Velden, Joanne et al.
UC Davis
UC Davis Previously Published Works
Title
K(Ca)3.1 channel-blockade attenuates airway pathophysiology in a sheep model of chronic 
asthma.
Permalink
https://escholarship.org/uc/item/3xs8b96v
Journal
PloS one, 8(6)
ISSN
1932-6203
Authors
Van Der Velden, Joanne
Sum, Grace
Barker, Donna
et al.
Publication Date
2013
DOI
10.1371/journal.pone.0066886
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
KCa3.1 Channel-Blockade Attenuates Airway
Pathophysiology in a Sheep Model of Chronic Asthma
Joanne Van Der Velden1,2, Grace Sum1, Donna Barker1, Emmanuel Koumoundouros1,3, Garry Barcham1,
Heike Wulff4, Neil Castle5, Peter Bradding6, Kenneth Snibson1*
1 Faculty of Veterinary Science, The University of Melbourne, Parkville, Victoria, Australia, 2 Lung Health Research Centre, Department of Pharmacology, University of
Melbourne, Parkville, Victoria, Australia, 3Department of Electrical and Electronic Engineering, University of Melbourne, Parkville, Victoria, Australia, 4Department of
Pharmacology, University of California Davis, Davis, California, United States of America, 5 Icagen Inc., Durham, North Carolina, United States of America, 6Department of
Infection, Immunity and Inflammation, Institute for Lung Health, University of Leicester, Leicester, United Kingdom
Abstract
Background: The Ca2+-activated K+ channel KCa3.1 is expressed in several structural and inflammatory airway cell types and
is proposed to play an important role in the pathophysiology of asthma. The aim of the current study was to determine
whether inhibition of KCa3.1 modifies experimental asthma in sheep.
Methodology and Principal Findings: Atopic sheep were administered either 30 mg/kg Senicapoc (ICA-17073), a selective
inhibitor of the KCa3.1-channel, or vehicle alone (0.5% methylcellulose) twice daily (orally). Both groups received fortnightly
aerosol challenges with house dust mite allergen for fourteen weeks. A separate sheep group received no allergen
challenges or drug treatment. In the vehicle-control group, twelve weeks of allergen challenges resulted in a 60619%
increase in resting airway resistance, and this was completely attenuated by treatment with Senicapoc (0.25612%; n= 10,
P = 0.0147). The vehicle-control group had a peak-early phase increase in lung resistance of 82621%, and this was reduced
by 58% with Senicapoc treatment (24614%; n = 10, P = 0.0288). Senicapoc-treated sheep also demonstrated reduced airway
hyperresponsiveness, requiring a significantly higher dose of carbachol to increase resistance by 100% compared to
allergen-challenged vehicle-control sheep (2065 vs. 52618 breath-units of carbachol; n = 10, P = 0.0340). Senicapoc also
significantly reduced eosinophil numbers in bronchoalveolar lavage taken 48 hours post-allergen challenge, and reduced
vascular remodelling.
Conclusions: These findings suggest that KCa3.1-activity contributes to allergen-induced airway responses, inflammation
and vascular remodelling in a sheep model of asthma, and that inhibition of KCa3.1 may be an effective strategy for blocking
allergen-induced airway inflammation and hyperresponsiveness in humans.
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Introduction
Asthma affects 300 million people worldwide and is a significant
cause of morbidity and mortality in developed countries. The
financial burden of asthma in the United States is estimated to be
over $10 billion. The disease is characterised by a complex of
airway inflammation, remodelling and bronchial hyperresponsive-
ness, leading to recurring episodes of potentially reversible airflow
limitation and in some patients fixed airflow obstruction.
Currently available therapies for the treatment of asthma are
ineffective at relieving symptoms in approximately 10% of patients
and offer no prospect of cure. These patients with apparently
refractory disease have significant morbidity and mortality, and
there is therefore an urgent need to identify better therapeutic
approaches to treat asthma.
Ion channels are emerging as interesting therapeutic targets for
the management of asthma, particularly ion cannels that directly
or indirectly facilitate the entry of calcium ions (Ca2+) into cells [1].
The KCa3.1 ion-channel is expressed by a wide variety of cells
involved in asthma including mast cells, T cells, airway epithelial
cells, fibroblasts, fibrocytes, and dedifferentiated, proliferative
airway smooth muscle cells [1,2]. Many of the complex cellular
processes mediated by these cells require a sustained elevation of
intracellular Ca2+, including cellular proliferation, chemotaxis,
mediator-release and for smooth muscle, contraction [3]. As the
influx of positively charged Ca2+ ions depolarises the cell
membrane, the driving force for Ca2+ entry soon diminishes.
However, rising cytoplasmic Ca2+ levels activate the Ca2+
activated K+ channel KCa3.1 resulting in K
+ efflux, which
maintains a negative membrane potential and sustains a driving
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force for Ca2+ entry [4,5]. Modulation of the KCa3.1 channel,
could therefore potentially limit the activity of several structural
and inflammatory cells that play important roles in disease
pathophysiology and lead to the development of new therapies for
the treatment of asthma [1].
To date, studies investigating the effects of KCa3.1 blockade in
relation to asthma have been encouraging. Studies have demon-
strated that blockade of KCa3.1 inhibits ASM cell proliferation
in vitro [2] and attenuates the chemotactic response of human lung
mast cells (HLMCs) to conditioned media from asthmatic ASM
[6]. Studies have also shown that allergen-induced mast cell
degranulation and IgE-mediated systemic anaphylactic responses
are attenuated in mice lacking the KCa3.1 channel [7]. While these
studies indicate that modulation of the KCa3.1 ion-channel could
be of potential therapeutic benefit in asthma, the effect of KCa3.1
blockade on airway remodelling, inflammatory responses and
functional airway responses in vivo is largely unknown.
In the present study we investigate the effect of KCa3.1-
inhibition, on in vivo airway responses and inflammation in a large
animal model of asthma. To achieve this, house dust mite (HDM)
sensitised sheep were treated twice daily with Senicapoc (ICA-
17073) or vehicle and challenged biweekly with HDM. We
examined the effect of KCa3.1-blockade on resting lung function
and airway responses to allergic and non-allergic stimuli. We also
studied the effect of this treatment on allergen-induced airway
remodelling and inflammatory responses in these sheep.
Methods
Experimental Animals and Allergen Sensitisation
Female Merino-cross sheep (6 months) were immunised with
HDM (50 mg/mL; Dermatophagoides pteronyssins; CSL, Parkville,
Australia) and atopic sheep selected as described previously [8]. All
experimental animal procedures and the collection of tissues/cells
were approved by the Animal Experimentation Ethics Committee
of the University of Melbourne.
Treatment
Sheep received either fortnightly challenges with HDM or no
treatment for fourteen weeks (n = 10 per group). For HDM
challenges sheep were ventilated (BEAR 2; Bear Medical Systems,
Palm Springs, USA) at 20 breaths per minute with a nebulised
1 mg/mL HDM solution for 10 minutes. HDM-challenged sheep
received twice daily oral dosing with a syringe of either 30 mg/kg
Senicapoc (Icagen Inc; Durham, USA) in vehicle, 0.5% Methyl-
celH MC (Sigma-Aldrich, Castle Hill, Australia) in distilled water,
or vehicle alone. Dosing commenced seven days prior to the first
HDM challenge and continued throughout the trial.
Lung Function
Measurement of lung function and airway responsiveness to
carbachol was assessed as previously described [9]. Airway
responsiveness is expressed as the concentration of carbachol
aerosol (1 breath unit [BU] is 1 breath of 1% w/v carbachol)
needed to increase lung resistance (RL) by 100% from baseline.
Bronchoalveolar Lavage
Bronchoalveolar lavage (BAL) cells were collected from sheep
before challenge and again at 48 hours after a HDM aerosol
challenge, four weeks into the repetitive challenge regime as
previously described [10]. Total and differential leukocyte counts
were performed as previously described [10].
Lung Tissue Collection, Immunohistochemistry and
Morphometric Analysis
Seven days after the final HDM challenge, sheep were
euthanised by intravenous barbiturate overdose (Lethabarb). Lung
segments from the left and right caudal lungs were removed and
inflated with optimal cutting temperature compound (ProSciTech,
Thuringoura, Australia) diluted in phosphate buffered saline (1:1).
Mast cells, eosinophils and blood vessels were identified immuno-
histochemically as previously described [11,12]. Mouse monoclo-
nal antibody supernatants against ovine cell types were used to
identify T-lymphocyte subpopulations: CD8, CD4, CD45,
CD45R and gammadelta (Centre for Animal Biotechnology).
HRP-conjugated secondary antibodies (Dako) and a peroxidase-
based detection system were used for visualization. Specificity of
staining was confirmed by omission of the primary antibody.
Collagen and ASM was stained and measured on sections as
previously described [11].
All morphometric measurements of the airways were made
using digital image analysis (Image-Pro Plus, Media Cybernetics,
version 4.1.0.0) by a single observer blinded to the experimental
group as previously described [11,12]. Measurements were made
on two small cartilaginous bronchi, approximately 1–2 mm
diameter, from each sheep and the two values averaged.
Statistical Analysis
All values are reported as mean 6 SEM. Data were analysed
using GraphPad Prism 5.0 statistical software (GraphPad Software
Inc., La Jolla, USA). Comparisons between different time-points
within one group were analysed with a Wilcoxon-signed rank test.
Comparisons between the vehicle and Senicapoc group were
performed using a Mann-Whitney test. A one-way ANOVA was
used to compare between three groups. A P value of ,0.05 was
taken as significant.
Results
Lung Function
There was an increase of 60620% between week 0 and week
12 in the resting lung resistance (RL) in HDM-challenged sheep
that received vehicle alone (P,0.05). An increase in RL was
inhibited completely by treatment with Senicapoc (0.25612%;
Fig. 1).
The peak early phase bronchoconstriction response following
HDM challenge was reduced by 58% in Senicapoc treated sheep
compared to sheep treated with vehicle alone (P,0.05; Fig. 2).
There was no pronounced late-phase response detected 5 or 24
hours following HDM-challenge in either the vehicle or
Senicapoc-treated sheep (data not shown). Senicapoc treatment
also resulted in a reduction in airway responsiveness to the
cholinergic agonist carbachol compared with vehicle 24-hours
post-HDM challenge. Sheep treated with Senicapoc required a
significantly higher dose of carbachol, (measured as an increase in
breath units (BU) of carbachol delivered), to increase RL by 100%
compared to sheep treated with vehicle (52618 vs. 2065; Fig. 3).
Bronchoalveolar Lavage
Table 1 shows the total and differential cell counts on BAL cells
collected prior to, and 48 hours following, the 4th HDM challenge
for both the vehicle and Senicapoc-treated sheep at Week 4 of the
fortnightly allergen challenge regime. Immediately before the 4th
HDM challenge (i.e. 7 days post 3rd HDM challenge), there were
significantly fewer neutrophils and lymphocytes in the resting BAL
of Senicapoc-treated sheep compared to vehicle-treated sheep
(P,0.05).
KCa3.1 Inhibition and Lung Function in Asthma
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The differential counts at 48 hours after the 4th HDM challenge
showed a rise in BAL eosinophils in the vehicle-treated group, and
this was markedly attenuated by Senicapoc treatment (P,0.05).
Interestingly, treatment with Senicapoc did not affect the total
leukocyte recruitment in BAL 48 hours following a HDM
challenge compared to vehicle. There were no differences between
the numbers of neutrophils, lymphocytes or macrophages in
retrieved in the BAL between any of the groups 48 hours following
HDM challenge (Table 1).
Eosinophil Density
Airway tissue collected post-mortem, for both the Senicapoc-
and vehicle-treated HDM-challenged groups there were greater
than 2-fold increases in eosinophil densities compared to untreated
controls (Fig. 4) (control 1664 cells/mm2, vehicle 36629 cells/
mm2, Senicapoc 4469 cells/mm2, P,0.05).
Mast Cell Density
In airway tissue collected post-mortem, mast cell density in the
airway wall was significantly increased in vehicle-treated HDM-
challenged sheep compared to untreated controls (355637 vs.
178642 cells/mm2, P,0.05; Fig. 5a). Mast cell density was also
higher in the airway walls of Senicapoc-treated HDM-challenged
sheep compared with controls (395662 vs. 178642 cells/mm2,
P,0.05; Fig. 5a). There were no significant differences in the
number of mast cells within the ASM bundles between any of the
groups (control: 3.261.0, vehicle: 5.661.4, Senicapoc: 3.960.9
cells/mm2, n = 10, P= 0.265).
Airway Remodelling
There was a significant increase in the density of blood vessels in
the airway wall in HDM-challenged sheep treated with vehicle
compared to control sheep (410624 vs. 289623 vessels/mm2,
P,0.05; Fig. 6a). Blood vessel density was also increased in the
Senicapoc-treated group of sheep but not significantly different
from either vehicle, or control groups (378621 vs. 289623
vessels/mm2, P= 0.312, Fig. 6a). Blood vessel size was similar in
control sheep and vehicle-treated HDM-challenged sheep, but
significantly decreased in Senicapoc-treated HDM-challenged
animals compared to controls (213611 vs. 26169 mm2 respec-
tively, P,0.05; Fig. 6b). There was no difference in ASM or
collagen area per mm2 basement membrane between any of the
groups (data not shown).
Figure 1. Comparison of resting lung resistance (RL) as
assessed prior to the first HDM challenge (week 0) and 12
weeks into the repeated challenge regime in sheep treated
with either vehicle or Senicapoc. Horizontal lines represent the
median, boxes represent the 25th and 75th percentiles, whiskers
represent the 5th and 95th percentiles. n = 10, **P,0.01.
doi:10.1371/journal.pone.0066886.g001
Figure 2. The percent acute change in lung resistance (RL)
following HDM challenge as assessed at week 12 in sheep
treated with either vehicle or Senicapoc. Dots represent data
points for individual sheep, lines show mean 6 SEM. n = 10, *P,0.05.
doi:10.1371/journal.pone.0066886.g002
Figure 3. Comparison of the number of breath units (BU) of
carbachol required to raise the lung resistance (RL) 100%
above the RL following the administration of saline (1 BU is
equal to 1 breath of 1% carbachol). Dots represent data points for
individual sheep, lines show mean 6 SEM. n = 10, *P,0.05.
doi:10.1371/journal.pone.0066886.g003
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T-lymphocyte Subpopulations
The number of CD8+ cells per mm2 in lung parenchyma was
significantly increased in the vehicle-treated HDM-challenged
group compared to unchallenged controls (2963 vs. 1562 cells/
mm2, P,0.05; Fig. 7). In contrast, in Senicapoc-treated sheep, the
density of CD8+ lymphocytes was significantly lower than that
found for both the HDM-challenged vehicle-treated sheep (762
vs. 2963 cells/mm2 P,0.05), and control sheep (762 vs. 1562
cells/mm2 P,0.05). The concentration of CD45+ cells was
decreased in vehicle-treated HDM-challenged sheep compared
to controls (3065 vs. 65614 cells/mm2, P,0.05), while for this
lymphocyte subset there were no difference between Senicapoc-
treated and control sheep (5968 vs. 65614 cells/mm2). There was
a significant decrease in the density of CD45R+ cells in the
Senicapoc-treated sheep compared to controls (461 vs. 963 cells/
mm2, P,0.05; Fig. 7). There were no significant differences in the
densities of CD4 and gammadelta positive-cells between any of the
groups (Fig. 7).
Discussion
The KCa3.1-channel is expressed by several structural and
inflammatory cells in the airways and is considered to play a
significant role in driving pathogenic changes associated with
asthma [1,2]. While to date much of the evidence supporting the
importance of KCa3.1-activity in allergic airways disease comes
from in vitro studies, results from the present study provide support
for the hypothesis that KCa3.1 activity plays an important role in
the generation of allergen-induced airway responses in vivo. In
particular, we have shown that KCa3.1-blockade via oral
Senicapoc administration was able to significantly reduce acute
allergen-dependent bronchoconstriction, the allergen-dependent
increase in lung resistance, and airway hyperresponsiveness (AHR)
to carbachol.
From previous work we would predict that the beneficial effects
observed with Senicapoc treatment with respect to lung physiology
would occur in part through the attenuation of mast cell activity.
Our study found no difference in the number of mast cells present
between the Senicapoc- and vehicle-treated sheep. This finding is
in line with previous studies, which demonstrate that KCa3.1
2/2
mice have normal mast cell numbers compared to wild-type mice
and that pharmacological inhibition of KCa3.1 does not attenuate
the proliferation of HLMCs in vitro [6,7]. It has previously been
reported that mast cell-degranulation is inhibited in mice that lack
the KCa3.1 channel, and in HLMCs exposed to KCa3.1 blockers
[7,13]. Attenuated mast-cell degranulation could therefore poten-
tially explain our observation that KCa3.1-blockade significantly
reduced the peak early-phase response to HDM, as this response
in sheep is a mast cell-dependent process [14].
The KCa3.1-channel is also expressed by both asthmatic and
non-asthmatic ASM, and its inhibition attenuates human ASM
proliferation in vitro [2]. It is therefore possible that long term
blockade of KCa3.1 is able to prevent increases in the amount of
ASM in asthmatic airways. Previous studies using the sheep model
have shown that 24–26 weeks of HDM challenge is sufficient to
induce airway-remodelling changes typical of asthma including
increases in airway collagen and ASM content [11,12]. However,
in the present study neither of these remodelling changes was
observed, suggesting that 14 weeks of HDM challenges was not
sufficient to induce structural airway changes. Thus, we are unable
to determine whether KCa3.1 blockade has any effect on structural
airway remodelling in asthma.
Blockade of the KCa3.1 channel block significantly reduced the
numbers of eosinophils in the BAL following allergen-challenge.
Surprisingly, treatment with Senicapoc had no effect on the
density of eosinophils in the airway tissue. KCa3.1-activity is
required for human mast cell and fibrocyte migration, and it
possible that this is also the case for eosinophil migration [6,15].
This is similar to reports of anti-IL-5 treatment, which markedly
reduces sputum eosinophils by is less effective at reducing tissue
eosinophils [16,17]. Furthermore, anti-IL-5 treatment has been
Table 1. Total and differential leukocyte counts were
performed on BAL cells collected from vehicle and Senicapoc
treated sheep prior to and 48 hours following the house dust
mite (HDM) challenge, at week 4.
vehicle Senicapoc
Pre-HDM challenge
Total leukocytes 35.660.5 20.160.3
Neutrophils 2.760.9 0.760.9*
Eosinophils 1.960.9 2.460.8
Lymphocytes 4.361.0 1.760.2*
Macrophages 26.366.8 15.062.2
48 hrs post-HDM challenge
Total leukocytes 48.060.8 42.061.011
Neutrophils 4.561.3 8.363.01
Eosinophils 16.464.911 4.161.1*
Lymphocytes 3.661.31 4.061.31
Macrophages 22.863.011 25.565.01
All values shown are6104 cells per mL BAL fluid. Values are the mean 6 SEM.
n = 10,
*P,0.05,
**P,0.01 compared to vehicle.
1P,0.05,
11P,0.01 compared to pre-HDM challenge.
doi:10.1371/journal.pone.0066886.t001
Figure 4. Eosinophils per mm2 airway wall in control sheep and
HDM challenged sheep treated with either vehicle or Senica-
poc. Dots represent data points for individual sheep, lines show mean
6 SEM. n= 10, *P,0.05 compared to control.
doi:10.1371/journal.pone.0066886.g004
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shown to be effective at reducing exacerbations in patients with
severe eosinophilic asthma [18]. This raises the possibility that
Senicapoc may have similar effects in this group of patients, and
could offer an alternative therapeutic option for patients with
relative steroid resistance.
Interestingly, while there was a significant increase in neutro-
phils 48 hours post-HDM-challenge in both the vehicle and
Senicapoc treated groups, the magnitude of the increase was ten-
fold higher in the Senicapoc treated group. Most of this change
was due to the significant reduction in the number of neutrophils
per mL in the Senicapoc group, compared to the vehicle treated
group, immediately prior to HDM challenge.
Endothelial cell proliferation and migration, which gives rise to
the formation of new blood vessels, is induced by an elevation in
angiogenic factors such as basic fibroblast growth factor (bFGF)
and vascular endothelial growth factor (VEGF) and is initiated by
a rise in intracellular Ca2+ [19]. Vascular remodeling is a feature
of asthma, and is inversely associated with the post-bronchodilator
FEV1 but not AHR [20]. In an in vivo mouse model of
angiogenesis KCa3.1-blockade via daily administration of
Figure 5. Mast cells per mm2 A) airway wall and B) airway smooth muscle (ASM) in control sheep and HDM-challenged sheep
treated either with vehicle or Senicapoc. Dots represent data points for individual sheep, lines show mean6 SEM. n = 10, *P,0.05 compared to
control.
doi:10.1371/journal.pone.0066886.g005
Figure 6. Blood vessel density and mean blood vessel size. A) vessels per mm2 airway wall B) mean blood vessel size (mm2) in control sheep
and HDM-challenged sheep treated wither with vehicle or Senicapoc. Dots represent data points for individual sheep, lines show mean6 SEM. n = 10,
*P,0.05 compared to control.
doi:10.1371/journal.pone.0066886.g006
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TRAM-34, another selective KCa3.1 channel blocker significantly
reduced bFGF- and VEGF-induced endothelial cell proliferation
and angiogenesis [21]. Our current results indicate that KCa3.1-
blockade also dampens an increase in vessel density in an in vivo
model of allergic airways disease. There is currently no published
data on the effect of KCa3.1-blockade on blood vessel size.
However, the results presented here show a significant reduction in
the mean size of vessels in the airway wall of Senicapoc-treated
sheep. It is possible that this reduced vessel calibre contributes to a
reduction in airway oedema in the airways following allergen
exposure, and thus accounts for some of the observed improve-
ments in lung function.
In asthmatic airways, T cells are believed to contribute to
disease pathophysiology through the release of a plethora of
cytokines that are involved in the induction of airway inflamma-
tion. In the present study we found a reduction in the number of
CD8 and CD45R positive T cells in the airway parenchyma of
Senicapoc-treated sheep compared to untreated controls and/or
vehicle treated sheep. This is in line with previous studies which
have demonstrated that KCa3.1-blockade via charybdotoxin,
clotrimazole and TRAM-34 have been shown to inhibit T cell
proliferation [22] as well as cytokine secretion in vitro [23].
However, the role, if any, for CD8+ T cells in asthma is uncertain
[24].
Targeting KCa3.1 is an attractive therapeutic target, as its
inhibition does not appear to have adverse effects on healthy
physiology. The KCa3.1-knockout mouse has a relatively healthy
phenotype, long-term treatment of animals with TRAM-34 has
not produced any severe adverse effects, and Senicapoc was well
tolerated in phase III trials of sickle cell disease when given for 48
weeks [4]. In a small phase II trial in patients with allergic asthma,
2 weeks treatment with Senicapoc attenuated the late-phase
response to allergen challenge and reduced the concentration of
exhaled nitric oxide [4].
In summary, this study has shown that the prolonged inhibition
of the KCa3.1 channel by oral Senicapoc administration is effective
at reducing the severity of allergen-induced early-phase broncho-
constriction, resting lung resistance, AHR, BAL eosinophilia and
vascular remodelling in this sheep model of experimental asthma.
These findings support the hypothesis that the KCa3.1 channel
plays an important role in asthma pathophysiology and indicate
that targeting this channel for several months could be an effective
and novel therapeutic strategy.
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